BetterLife Pharma Inc.
BETRF · OTC
1/31/2025 | 1/31/2024 | 1/31/2023 | 1/31/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.60 | 0.04 | 0.04 | 0.01 |
| FCF Yield | -12.63% | -30.07% | -11.75% | -71.77% |
| EV / EBITDA | 0.00 | -3.03 | -1.51 | -1.41 |
| Quality | ||||
| ROIC | 82.51% | 54.44% | 167.20% | 377.19% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.56 | 0.85 | 0.16 | 0.92 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | 18.23% | -64.44% | 86.58% | -54.28% |
| Safety | ||||
| Net Debt / EBITDA | 0.00 | -0.45 | -0.13 | -0.10 |
| Interest Coverage | -15.65 | -63.66 | -140.83 | -174.96 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | -77,964.93 | -66,151.02 |